Total Funding
61
63
Total FundingSeries A raised
Growth Score
-4 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
88792
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
- Christian Schetter: Executive ChairmanPast Role: Rigontec, Chief Executive Officer
- Richard Sainson: Chief Scientific OfficerPast Role: Advesya, Chief Scientific Officer
About the Company
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds
that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.
